ADOA Program - SRC Approve Progression to Multi-Dose Study
Filed with ASX · · 3 pages · English
PYC Therapeutics Limited on 6ix
Earlier from PYC Therapeutics
- Completion of Retail Entitlement Offer
- PKD Clinical Trial - Approval to Escalate Dosing
- Half Yearly Report and Accounts
- Retail Offer Booklet
- Completion of Placement and Institutional Entitlement Offer
Later from PYC Therapeutics
- Presentation of Ophthalmology Clinical Trial Data at ARVO
- PKD - Initiation of Multiple Dose Clinical Trial
- ADOA Program Update
- PKD - Safety Committee Approves Dose Escalation
- S&P DJI Announces September 2026 Quarterly Rebalance
Follow PYC Therapeutics into a list and get an email when it puts out news.
Follow PYC Therapeutics